BR112021015616A2 - Ligantes de pseudoquinase tyk2 - Google Patents

Ligantes de pseudoquinase tyk2

Info

Publication number
BR112021015616A2
BR112021015616A2 BR112021015616A BR112021015616A BR112021015616A2 BR 112021015616 A2 BR112021015616 A2 BR 112021015616A2 BR 112021015616 A BR112021015616 A BR 112021015616A BR 112021015616 A BR112021015616 A BR 112021015616A BR 112021015616 A2 BR112021015616 A2 BR 112021015616A2
Authority
BR
Brazil
Prior art keywords
ligands
tyk2 pseudokinase
tyk2
pseudokinase ligands
disorders
Prior art date
Application number
BR112021015616A
Other languages
English (en)
Inventor
Jason Harris
John Nuss
Raju Mohan
Shendong Yuan
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of BR112021015616A2 publication Critical patent/BR112021015616A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ligantes de pseudoquinase tyk2. são descritos no presente documento ligantes de pseudoquinase tyk2 e métodos de utilização de ligantes de pseudoquinase tyk2 no tratamento de doenças, transtornos ou condições. também são descritas no presente documento composições farmacêuticas contendo tais compostos.
BR112021015616A 2019-02-07 2020-02-07 Ligantes de pseudoquinase tyk2 BR112021015616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
BR112021015616A2 true BR112021015616A2 (pt) 2021-11-09

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015616A BR112021015616A2 (pt) 2019-02-07 2020-02-07 Ligantes de pseudoquinase tyk2

Country Status (12)

Country Link
US (1) US20220135567A1 (pt)
EP (1) EP3920931A4 (pt)
JP (1) JP2022519696A (pt)
KR (1) KR20210124409A (pt)
CN (1) CN113677347A (pt)
AU (1) AU2020218267A1 (pt)
BR (1) BR112021015616A2 (pt)
CA (1) CA3129438A1 (pt)
IL (1) IL285429A (pt)
MX (1) MX2021009555A (pt)
SG (1) SG11202108619SA (pt)
WO (1) WO2020163778A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086616A1 (en) 2018-10-22 2020-04-30 Fronthera U.S. Pharmaceuticals Llc Tyk2 inhibitors and uses thereof
KR20220004641A (ko) 2019-03-26 2022-01-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나아제 리간드
WO2021092246A1 (en) 2019-11-08 2021-05-14 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP2023541203A (ja) * 2020-09-16 2023-09-28 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP4281458A1 (en) * 2021-01-19 2023-11-29 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
IL312330A (en) 2021-10-25 2024-06-01 Kymera Therapeutics Inc TYK2 joints and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516824A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
US10336752B2 (en) * 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
US20180334465A1 (en) * 2017-05-22 2018-11-22 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
BR112020001714A2 (pt) * 2017-07-28 2020-07-21 Nimbus Lakshmi, Inc. inibidores de tyk2 e usos dos mesmos
EP3849981B1 (en) * 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AR117177A1 (es) * 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa

Also Published As

Publication number Publication date
AU2020218267A1 (en) 2021-09-30
MX2021009555A (es) 2021-10-13
EP3920931A4 (en) 2022-08-10
US20220135567A1 (en) 2022-05-05
WO2020163778A1 (en) 2020-08-13
IL285429A (en) 2021-09-30
KR20210124409A (ko) 2021-10-14
CN113677347A (zh) 2021-11-19
SG11202108619SA (en) 2021-09-29
JP2022519696A (ja) 2022-03-24
CA3129438A1 (en) 2020-08-13
EP3920931A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
BR112021015616A2 (pt) Ligantes de pseudoquinase tyk2
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
PH12018501877A1 (en) Substituted indole mcl-1 inhibitors
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
EA202091709A1 (ru) Ингибиторы днк-пк
BR112019001439A8 (pt) compostos e composições e usos dos mesmos
BR112021022380A2 (pt) Inibidores de jak
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
EA202091708A1 (ru) Ингибиторы днк-пк
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
BR112022000855A2 (pt) Moduladores de nlrp3
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
BR112022018480A2 (pt) Moduladores de nlrp3
BR112021014566A2 (pt) Moduladores de gpr35
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
BR112022002390A2 (pt) Inibidores de jak